

# PICO 1

## Characteristics of studies

### Characteristics of included studies

#### Abbott 2013

<b>Methods</b>	
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Identification</b>	
<b>Notes</b>	

### Risk of bias table

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Sequence Generation	Low risk	RoB er taget Fra SR Fransen 2014
Incomplete outcome data	Low risk	
Allocation concealment	Low risk	
Blinding of participants and personnel	High risk	
Blinding of outcome assessors	Unclear risk	n
Selective outcome reporting	Low risk	
Other sources of bias	Unclear risk	n

**Fernandes 2010**

<b>Methods</b>	
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Identification</b>	
<b>Notes</b>	

**Risk of bias table**

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Sequence Generation	Low risk	Fransen et al. 2014
Incomplete outcome data	Low risk	
Allocation concealment	Low risk	
Blinding of participants and personnel	High risk	Physiotherapists and participants aware of treatment allocation
Blinding of outcome assessors	Unclear risk	Blinded outcomes assessor, but participant self reported pain and function
Selective outcome reporting	Low risk	
Other sources of bias	Low risk	

**French 2013**

<b>Methods</b>	
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Identification</b>	

<b>Notes</b>
--------------

**Risk of bias table**

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Sequence Generation	Low risk	RoB er taget Fra SR Fransen 2014
Incomplete outcome data	Low risk	
Allocation concealment	Low risk	
Blinding of participants and personnel	High risk	
Blinding of outcome assessors	Unclear risk	n
Selective outcome reporting	Low risk	
Other sources of bias	Low risk	

**Juhakoski 2011**

<b>Methods</b>
<b>Participants</b>
<b>Interventions</b>
<b>Outcomes</b>
<b>Identification</b>
<b>Notes</b>

**Risk of bias table**

Bias	Authors' judgement	Support for judgement
Sequence Generation	Low risk	RoB er taget Fra SR Fransen 2014
Incomplete outcome data	Low risk	
Allocation concealment	Low risk	
Blinding of participants and personnel	High risk	
Blinding of outcome assessors	Unclear risk	n
Selective outcome reporting	Unclear risk	n
Other sources of bias	Low risk	

### Oosting 2012

<p><b>Methods</b></p> <p><b>Study design:</b> Randomized controlled trial  <b>Study grouping:</b> Parallel group  <b>Open Label:</b>  <b>Cluster RCT:</b></p>	<p><b>Study design:</b> Randomized controlled trial  <b>Study grouping:</b> Parallel group  <b>Open Label:</b>  <b>Cluster RCT:</b></p>
<p><b>Participants</b></p> <p><b>Baseline Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● <i>Beskrivelse:</i></li> <li>● <i>Female gender (%)</i>: 93</li> <li>● <i>Chair rise time (sec)</i>: 47.5 sec</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● <i>Beskrivelse:</i></li> <li>● <i>Female gender (%)</i>: 67</li> <li>● <i>Chair rise time (sec)</i>: 32.7 sec</li> </ul> <p><b>Included criteria:</b> Inclusion criteria were (1) elective THA (minimum waiting period of 3wk), (2) OA as underlying diagnosis for THA, (3) age older than 65 years, and (4) a score of 2 or higher on the frailty index Identification of Seniors At Risk (ISAR)  <b>Excluded criteria:</b> Exclusion criteria were (1) unable to understand Dutch, (2) inadequate cognitive functioning (ie, not able to understand instructions), (3) revision of THA, and (4) diagnosed with dementia or severe heart disease.</p>	<p><b>Baseline Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● <i>Beskrivelse:</i></li> <li>● <i>Female gender (%)</i>: 93</li> <li>● <i>Chair rise time (sec)</i>: 47.5 sec</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● <i>Beskrivelse:</i></li> <li>● <i>Female gender (%)</i>: 67</li> <li>● <i>Chair rise time (sec)</i>: 32.7 sec</li> </ul> <p><b>Included criteria:</b> Inclusion criteria were (1) elective THA (minimum waiting period of 3wk), (2) OA as underlying diagnosis for THA, (3) age older than 65 years, and (4) a score of 2 or higher on the frailty index Identification of Seniors At Risk (ISAR)  <b>Excluded criteria:</b> Exclusion criteria were (1) unable to understand Dutch, (2) inadequate cognitive functioning (ie, not able to understand instructions), (3) revision of THA, and (4) diagnosed with dementia or severe heart disease.</p>

	<p><b>Pretreatment:</b> More females in the intervention group compared to control (93% versus 97%). Higher (slower) Chair rise time at baseline in intervention group compared to control (47.5 versus 32.7 sec)</p> <p><b>Intervention Characteristics</b> Intervention</p> <ul style="list-style-type: none"> <li>● <i>Exercise description:</i> Functional activities and walking capacity.</li> <li>● <i>Exercise dose (intensity, frequency, duration):</i> Moderate intensity (55-75% of max, 11-13 on Borg scale). Intensity + repetitions progressively increased over time. 30 min/sessions twice a week for 3-6 weeks. Additional 4 times/week home-based exe</li> <li>● <i>Supervised sessions:</i> 6-12 sessions. Twice a week for 3-6 weeks. Median of 7 (range 5-8) sessions received.</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● <i>Exercise description:</i> Usual care, single group session 3 weeks before surgery. They received information about the operation, walking with crutches, and exercises that would be performed in the postoperative phase.</li> <li>● <i>Exercise dose (intensity, frequency, duration):</i> None</li> <li>● <i>Supervised sessions:</i> None</li> </ul>
<p><b>Outcomes</b></p>	<p><i>Patientrapporteret funksjonsevne</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> ContinuousOutcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> HOOS function</li> <li>● <b>Range:</b> 0-100</li> <li>● <b>Unit of measure:</b> Points</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> <li>● <b>Notes:</b> Converted scale</li> </ul> <p><i>Præstationsbaseret funksjonsevne</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> ContinuousOutcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Chair rise stand</li> <li>● <b>Unit of measure:</b> Seconds</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> <li>● <b>Notes:</b> Unknown number of repetitions</li> </ul>

	<p><i>Smerte (hofte)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> ContinuousOutcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> HOOS Pain</li> <li>● <b>Range:</b> 0-100</li> <li>● <b>Unit of measure:</b> Points</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> <li>● <b>Notes:</b> Converted scale</li> </ul> <p><i>Helbredsrelatered livskvalitet</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> ContinuousOutcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> HOOS QOL</li> <li>● <b>Range:</b> 0-100</li> <li>● <b>Unit of measure:</b> Points</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> <li>● <b>Notes:</b> Converted scale</li> </ul> <p><i>Træningsinducerede skader</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> AdverseEvent</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p><i>Smerte (ikke hofterelateret)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> AdverseEvent</li> <li>● <b>Reporting:</b> Not reported</li> </ul>
<b>Identification</b>	<p><b>Sponsorship source:</b> Supported by the Scientific College Physical Therapy of the Royal Dutch Society for Physical Therapy</p> <p><b>Country:</b> The Netherlands</p> <p><b>Setting:</b></p> <p><b>Comments:</b></p> <p><b>Authors name:</b> Oosting, 2012</p>

<b>Institution:</b> <b>Email:</b> <b>Address:</b>	
<b>Notes</b>	

### Risk of bias table

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Sequence Generation	Low risk	Quote: "Randomization took place after stratification by age (65–70y and age 70y), using prepared envelopes per stratum. Within each stratum a permuted block randomization with a block size of 10 was used."
Incomplete outcome data	Low risk	Judgement Comment: Low drop out rates
Allocation concealment	Low risk	Judgement Comment: Concealed by permuted blocks
Blinding of participants and personnel	High risk	Judgement Comment: Not possible
Blinding of outcome assessors	Low risk	Judgement Comment: Blinded outcome assessors
Selective outcome reporting	Low risk	Judgement Comment: None apparent, pilot study
Other sources of bias	Low risk	Judgement Comment: None apparent

### Teirlinck 2016

<b>Methods</b>	<b>Study design:</b> Randomized controlled trial <b>Study grouping:</b> Parallel group <b>Open Label:</b> <b>Cluster RCT:</b>
<b>Participants</b>	<b>Baseline Characteristics</b> Intervention <ul style="list-style-type: none"> <li>● <i>Beskrivelse:</i></li> </ul>

	<p>Control</p> <ul style="list-style-type: none"> <li>● <i>Beskrivelse:</i></li> </ul> <p><b>Included criteria:</b> Patients were eligible if they were aged 45 years, and suffered from a new episode of non-traumatic hip complaints fulfilling the clinical criteria for hip OA of the American College of Rheumatology (ACR)</p> <p><b>Excluded criteria:</b> Exclusion criteria: - exercise therapy in the past 3 months; - hip pain score &lt;2 on an 11-point numeric rating scale (NRS: 0 ¼ no pain); - high level of physical function (score of &lt;2 on the Algofunctional Index) 13, - hip surgery or on waiting list; - disabling co-morbidity (e.g., severe heart failure); - insufficient comprehension of the Dutch language; - mentally incapable of participation</p> <p><b>Pretreatment:</b></p>
<p><b>Interventions</b></p>	<p><b>Intervention Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● <i>Exercise description:</i> Exercises consisted of strengthening and improving flexibility of muscles around the hip joint (especially extensors and abductors), leg and abdominal muscles. Aerobic exercises to improve endurance were also included. Passive treatment forms were not allowed. Patients were expected to perform home exercises and were provided a booklet describing the exercises</li> <li>● <i>Exercise dose (intensity, frequency, duration):</i> 30 minutes, 1/week during 3 months</li> <li>● <i>Supervised sessions:</i> Target max 12 sessions + 2 booster sessions. Median 8 sessions received</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● <i>Exercise description:</i> GP care could include education, counselling, prescription of pain medication, additional diagnostic tests or referral to an orthopedic surgeon. In the control group, referral to a physical therapist was discouraged, but was not restricted</li> <li>● <i>Exercise dose (intensity, frequency, duration):</i></li> <li>● <i>Supervised sessions:</i> Unknown</li> </ul>
<p><b>Outcomes</b></p>	<p><i>Patientrapporteret funktionsevne</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> HOOS ADL</li> <li>● <b>Range:</b> 0-100</li> <li>● <b>Unit of measure:</b> Points</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul>

- **Notes:** Obs konverteret skala - lower is better

*Præstationsbaseret funktionsevne*

- **Outcome type:** ContinuousOutcome
- **Reporting:** Not reported
- **Unit of measure:** seconds
- **Direction:** Lower is better
- **Data value:** Endpoint

*Smerte (hofte)*

- **Outcome type:** ContinuousOutcome
- **Reporting:** Fully reported
- **Scale:** HOOS Pain
- **Range:** 0-100
- **Unit of measure:** Points
- **Direction:** Lower is better
- **Data value:** Endpoint
- **Notes:** Converted scale

*Helbredsrelateret livskvalitet*

- **Outcome type:** ContinuousOutcome
- **Reporting:** Fully reported
- **Scale:** EQ-5D
- **Range:** -0.329-1
- **Unit of measure:** Points
- **Direction:** Higher is better
- **Data value:** Endpoint

*Træningsinducerede skader*

- **Outcome type:** AdverseEvent
- **Reporting:** Not reported
- **Data value:** Endpoint

*Smerte (ikke hofterelateret)*

- **Outcome type:** AdverseEvent
- **Reporting:** Not reported

<b>Identification</b>	<p><b>Sponsorship source:</b> Netherlands Organization for Health Research and Development(Health Care Efficiency Research Program), Dutch Arthritis Foundation, the NetherlandsOrganization for Health Research and Development, Fonds Nuts Ohra, the European Union, Dutch Arthritis Foundatio and personal fees from Biomedis International LTD (Japan).</p> <p><b>Country:</b> The Netherlands</p> <p><b>Setting:</b></p> <p><b>Comments:</b></p> <p><b>Authors name:</b> Teirlinck, 2016</p> <p><b>Institution:</b></p> <p><b>Email:</b></p> <p><b>Address:</b></p>
<b>Notes</b>	

### Risk of bias table

Bias	Authors' judgement	Support for judgement
Sequence Generation	Low risk	Quote: "For the random allocation sequence (allocation ratio 1:1) a computer-generated random table was used, provided by an in- dependent person. Block randomization was used with random blocks of 4, 6 and 8 patients."
Incomplete outcome data	Low risk	Judgement Comment: Low drop out rates and intention-to-treat analysis performed
Allocation concealment	Low risk	Quote: "Based on the randomization list, opaque, sealed, sequentially numbered envelopes were prepared by an independent person. In this way the member of the research team was blinded for treatment allocation."
Blinding of participants and personnel	High risk	Quote: "Blinding for subsequent treatment of patient, of care provider and researcher during follow-up was not possible due to the intervention of interest."
Blinding of outcome assessors	Low risk	Judgement Comment: Only patient-reported outcomes are used
Selective outcome reporting	Low risk	Judgement Comment: Pre-registered trial and changes to trial since protocol are described
Other sources of bias	Low risk	Judgement Comment: None apparent

**van Baar 1998**

<b>Methods</b>	
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Identification</b>	
<b>Notes</b>	

**Risk of bias table**

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Sequence Generation	Low risk	
Incomplete outcome data	Low risk	
Allocation concealment	Low risk	
Blinding of participants and personnel	High risk	
Blinding of outcome assessors	Unclear risk	n
Selective outcome reporting	Unclear risk	n
Other sources of bias	Low risk	

**Villadsen 2014**

<b>Methods</b>	<p><b>Study design:</b> Randomized controlled trial  <b>Study grouping:</b> Parallel group  <b>Open Label:</b>  <b>Cluster RCT:</b></p>
----------------	---

<p><b>Participants</b></p>	<p><b>Baseline Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● <i>Beskrivelse:</i></li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● <i>Beskrivelse:</i></li> </ul> <p><b>Included criteria:</b> Eligible patients were at least 18 years of age and scheduled for primary unilateral total hip or knee replacement at the Svendborg Hospital, Odense University Hospital, Denmark, because of symptomatic OA</p> <p><b>Excluded criteria:</b> Exclusion criteria were current or previous fractures in or adjacent to the joint, inflammatory arthritis and comorbidity diseases, e.g., severe heart disease and neurological deficits, making exercise and testing impossible. Patients were not included if scheduled for bilateral TJR in the same procedure or for geographic reasons, e.g., living on adjacent islands with logistics making frequent attendance unrealistic</p> <p><b>Pretreatment:</b></p>
<p><b>Interventions</b></p>	<p><b>Intervention Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● <i>Exercise description:</i> Neuromuscular training (NEMEX-TJR) + Standard preoperative information as control group</li> <li>● <i>Exercise dose (frequency, duration, progression):</i> 1 hour twice a week for 8 weeks, Individualization is possible through progression of the level of difficulty of each exercise based on the equality of the performance evaluated by the supervising physiotherapist.</li> <li>● <i>Number of exercise session with/without supervision:</i> 16-18 supervised sessions</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● <i>Exercise description:</i> Standard preoperative information including exercise leaflet</li> <li>● <i>Exercise dose (frequency, duration, progression):</i> None</li> <li>● <i>Number of exercise session with/without supervision:</i> None</li> </ul>
<p><b>Outcomes</b></p>	<p><i>Patientrapporteret funktionsevne</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> HOOS ADL</li> <li>● <b>Range:</b> 0-100</li> <li>● <b>Unit of measure:</b> Points</li> <li>● <b>Direction:</b> Higher is better</li> </ul>

- **Data value:** Change from baseline

*Præstationsbaseret funktionsevne*

- **Outcome type:** ContinuousOutcome
- **Reporting:** Fully reported
- **Scale:** Chair stand test (5 rep)
- **Unit of measure:** Seconds
- **Direction:** Lower is better
- **Data value:** Change from baseline

*Smerte (hofte)*

- **Outcome type:** ContinuousOutcome
- **Reporting:** Fully reported
- **Scale:** HOOS Pain
- **Range:** 0-100
- **Unit of measure:** Points
- **Direction:** Higher is better
- **Data value:** Change from baseline

*Helbredsrelateret livskvalitet*

- **Outcome type:** ContinuousOutcome
- **Reporting:** Fully reported
- **Scale:** HOOS QOL
- **Range:** 0-100
- **Unit of measure:** Points
- **Direction:** Higher is better
- **Data value:** Change from baseline

*Træningsinducerede skader*

- **Outcome type:** AdverseEvent
- **Reporting:** Partially reported

*Smerte (ikke hofterelateret)*

- **Outcome type:** AdverseEvent
- **Reporting:** Not reported

<b>Identification</b>	<p><b>Sponsorship source:</b> Tryg Fonden (number7-10-0094). Protesekompagniet, a private Danish corporation supplying orthopedic equipment, funded the exercise machines used for patient assessments. The Parker Institute is supported by grants from the Oak Foundation.A. Villadsen is co-owner of the Danish company Ther-ex (34595208), which produces an exercise application.</p> <p><b>Country:</b> Denmark</p> <p><b>Setting:</b></p> <p><b>Comments:</b></p> <p><b>Authors name:</b> Villadsen</p> <p><b>Institution:</b></p> <p><b>Email:</b></p> <p><b>Address:</b></p>
<b>Notes</b>	

### Risk of bias table

Bias	Authors' judgement	Support for judgement
Sequence Generation	Low risk	Judgement Comment: Using sequentially numbered, opaque, sealed envelopes produced by a person not otherwise involved in the trial.
Incomplete outcome data	Low risk	Judgement Comment: Low drop out rates + intention-to-treat analysis
Allocation concealment	Low risk	Judgement Comment: Allocation concealed by opaque, sealed envelopes, block randomisation in groups of 4. Instruction to patients concerning not to reveal their group assignment to assessors.
Blinding of participants and personnel	High risk	Judgement Comment: Not possible to blind
Blinding of outcome assessors	Low risk	Judgement Comment: Blinded assessment + blinded analysis
Selective outcome reporting	Low risk	Judgement Comment: None apparent, pre-registered trial
Other sources of bias	Low risk	

*Footnotes*

## References to studies

### Included studies

#### **Abbott 2013**

*Published and unpublished data*

[Empty]

#### **Fernandes 2010**

L. Fernandes yz\*, K. Storheimyz, L. Sandvik x, L. Nordsetten k{, M.A. Risberg yz#.

#### **French 2013**

[Empty]

#### **Juhakoski 2011**

*Published and unpublished data*

[Empty]

#### **Oosting 2012**

Oosting E.; Jans M.P.; Dronkers J.J.; Naber R.H.; Dronkers-Landman C.M.; Appelman-De Vries S.; Van, Meeteren N.. Preoperative home-based physical therapy versus usual care to improve functional health of frail older adults scheduled for elective total hip arthroplasty: A pilot randomized controlled trial. Archives of Physical Medicine and Rehabilitation 2012;93(4):610-616. [DOI: ]

#### **Teirlinck 2016**

Teirlinck C.H.; Luijsterburg P.A.J.; Dekker J.; Bohnen A.M.; Verhaar J.A.N.; Koopmanschap M.A.; van, Es P.; Koes B.W.; Bierma-Zeinstra S.M.A.. Effectiveness of exercise therapy added to general practitioner care in patients with hip osteoarthritis: A pragmatic randomized controlled trial. Osteoarthritis and Cartilage 2016;24(1):82-90. [DOI: ]

**van Baar 1998**

[Empty]

**Villadsen 2014**

Villadsen A.; Overgaard S.; Holsgaard-Larsen A.; Christensen R.; Roos E.M.. Immediate efficacy of neuromuscular exercise in patients with severe osteoarthritis of the hip or knee: A secondary analysis from a randomized controlled trial. *Journal of Rheumatology* 2014;41(7):1385-1394. [DOI: ]

## Data and analyses


### 1 Intervention vs Control

Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate
1.1 Patientrapporteret funktionsevne - Efter endt behandling	7		Std. Mean Difference (IV, Random, 95% CI)	Subtotals only
1.1.1 Patientrapporteret funktionsevne - Efter endt behandling (final score)	5	542	Std. Mean Difference (IV, Random, 95% CI)	-0.30 [-0.47, -0.13]
1.1.3 Patientrapporteret funktionsevne - Efter endt behandling (change)	2	233	Std. Mean Difference (IV, Random, 95% CI)	-0.17 [-1.17, 0.82]
1.2 Patientrapporteret funktionsevne - Langtidseffekt (6-12 mdr)	4		Std. Mean Difference (IV, Random, 95% CI)	Subtotals only
1.2.1 Patientrapporteret funktionsevne - Langtidseffekt (6-12 mdr) (final score)	3	337	Std. Mean Difference (IV, Random, 95% CI)	-0.39 [-0.60, -0.17]
1.2.2 Patientrapporteret funktionsevne - Langtidseffekt (6-12 mdr) (change)	1	65	Std. Mean Difference (IV, Random, 95% CI)	-0.07 [-0.56, 0.42]
1.3 Præstationsbaseret funktionsevne	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
1.3.2 Præstationsbaseret funktionsevne - Efter endt behandling (change)	2	191	Mean Difference (IV, Random, 95% CI)	-5.64 [-16.66, 5.39]

1.4 Smerte (hofte) final score	6				Subtotals only
1.4.1 Smerteniveau - hofterelateret (Efter endt behandling - final score)	6	614			-6.27 [-10.53, -2.00]
1.5 Smerte (hofte) change	1				Subtotals only
1.5.2 Smerteniveau - hofterelateret (Efter endt behandling - change)	1	165			8.40 [3.97, 12.83]
1.6 Helbredsrelateret livskvalitet (final score)	4				Subtotals only
1.6.1 Helbredsrelateret livskvalitet Efter endt behandling (final score)	4	426			0.04 [-0.15, 0.23]
1.7 Helbredsrelateret livskvalitet - change	1				Subtotals only
1.7.2 Helbredsrelateret livskvalitet Efter endt behandling (change)	1	165			-4.90 [-10.03, 0.23]


## Figures

### Figure 1 (Analysis 1.1)




Forest plot of comparison: 1 Intervention vs Control, outcome: 1.1 Patientrapporteret funktionsevne - Efter endt behandling.

**Figure 2 (Analysis 1.2)**




Forest plot of comparison: 1 Intervention vs Control, outcome: 1.2 Patientrapporteret funktionsevne - Langtidseffekt (6-12 mdr).

Figure 3 (Analysis 1.3)




Forest plot of comparison: 1 Intervention vs Control, outcome: 1.3 Præstationsbaseret funktionsevne.

Figure 4 (Analysis 1.4)




Forest plot of comparison: 1 Intervention vs Control, outcome: 1.4 Smerte (hofte) final score.

Figure 5 (Analysis 1.6)




Forest plot of comparison: 1 Intervention vs Control, outcome: 1.6 Helbredsrelateret livskvalitet (final score).

**Figure 6 (Analysis 1.7)**



Forest plot of comparison: 1 Intervention vs Control, outcome: 1.7 Helbredsrelateret livskvalitet - change.

**Figure 7 (Analysis 1.5)**



Forest plot of comparison: 1 Intervention vs Control, outcome: 1.5 Smerte (hofte) change.